This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Casarez, E. V. Articles by Amorino, G. P. Search for Related Content PubMed PubMed Citation Articles by Casarez, E. V. Articles by Amorino, G. P.

Radiosensitization and Modulation of p44/42 Mitogen-Activated Protein Kinase by 2-Methoxyestradiol in Prostate Cancer Models

Departments of ¹ Radiation Oncology and ² Microbiology, ³ Cancer Center, and ⁴ Division of Biostatistics, University of Virginia Health Sciences Center, Charlottesville, Virginia

Requests for reprints: George P. Amorino, Department of Radiation Oncology, University of Virginia Health System, P.O. Box 800383, Charlottesville, VA 22908. Phone: 434-924-5564; Fax: 434-243-9789; E-mail: ga4a{at}virginia.edu.

2-Methoxyestradiol (2ME2) is an endogenous estradiol metabolite that inhibits microtubule polymerization, tumor growth, and angiogenesis. Because prostate cancer is often treated with radiotherapy, and 2ME2 has shown efficacy as a single agent against human prostate carcinoma, we evaluated 2ME2 as a potential radiosensitizer in prostate cancer models. A dose-dependent decrease in mitogen-activated protein kinase phosphorylation was observed in human PC3 prostate cancer cells treated with 2ME2 for 18 h. This decrease correlated with in vitro radiosensitization measured by clonogenic assays, and these effects were blocked by the expression of constitutively active MEK. Male nude mice with subcutaneous PC3 xenografts in the hind leg were treated with 2ME2 (75 mg/kg) p.o. for 5 days, and 2 Gy radiation fractions were delivered each day at 4 h after drug treatment. A statistically significant super-additive effect between radiation and 2ME2 was observed in this subcutaneous model, using analysis of within-animal slopes. A PC-3M orthotopic model was also used, with bioluminescence imaging as an end point. PC-3M cells stably expressing the luciferase gene were surgically implanted into the prostates of male nude mice. Mice were given oral doses of 2ME2 (75 mg/kg), with radiation fractions (3 Gy) delivered 4 h later. Mice were then imaged weekly for 4 to 5 weeks with a Xenogen system. A significant super-additive effect was also observed in the orthotopic model. These data show that 2ME2 is an effective radiosensitizing agent against human prostate cancer xenografts, and that the mechanism may involve a decrease in mitogen-activated protein kinase phosphorylation by 2ME2. [Cancer Res 2007;67(17):8316–24]

This article has been cited by other articles:

				S. Kato, A. Sadarangani, S. Lange, A. M. Delpiano, M. Vargas, J. Branes, J. Carvajal, S. Lipkowitz, G. I. Owen, and M. A. Cuello 2-Methoxyestradiol Mediates Apoptosis Through Caspase-Dependent and Independent Mechanisms in Ovarian Cancer Cells But Not in Normal Counterparts Reproductive Sciences, November 1, 2008; 15(9): 878 - 894. [Abstract] [PDF]